Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and absolute bioavailability study of PF-07081532 in healthy male participants
NL-OMON51763Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Pfizer. Primary endpoints: Extent of excretion of total radioactivity in urine and feces and Metabolic profile and metabolite identification. Started Dec 2022; status: active, not recruiting.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON51763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51763.